Illumina, Inc. (NASDAQ:ILMN) Stock Position Reduced by EntryPoint Capital LLC

EntryPoint Capital LLC lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 59.9% during the first quarter, HoldingsChannel reports. The institutional investor owned 630 shares of the life sciences company’s stock after selling 943 shares during the quarter. EntryPoint Capital LLC’s holdings in Illumina were worth $87,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bouvel Investment Partners LLC raised its position in shares of Illumina by 1.3% during the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after purchasing an additional 84 shares during the period. STF Management LP increased its position in Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after acquiring an additional 90 shares during the period. Global Retirement Partners LLC increased its position in Illumina by 12.3% in the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after acquiring an additional 94 shares during the period. Gulf International Bank UK Ltd increased its position in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after acquiring an additional 98 shares during the period. Finally, Clear Creek Financial Management LLC increased its position in Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after acquiring an additional 100 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 3.8 %

NASDAQ ILMN traded up $4.47 during trading on Friday, hitting $121.77. 736,616 shares of the company traded hands, compared to its average volume of 2,127,210. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64. The business has a fifty day simple moving average of $109.69 and a 200 day simple moving average of $124.39. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $19.40 billion, a P/E ratio of -14.39 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the company earned $0.08 earnings per share. The business’s revenue was down 1.0% compared to the same quarter last year. As a group, sell-side analysts predict that Illumina, Inc. will post 1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ILMN shares. Barclays lifted their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. TD Cowen lowered their price target on Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research report on Thursday, June 6th. Robert W. Baird lifted their price target on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Royal Bank of Canada lowered their price target on Illumina from $249.00 to $242.00 and set an “outperform” rating on the stock in a research report on Monday, July 1st. Finally, Citigroup raised Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price objective for the company in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.